Home	Quick Product Lists	Contact LC Labs	Login/Register	My Account	View Cart
In Business 29 Years - Since 1980		THE CURRENT TIME at LC Labs is:

L-5499 (R,S)-Lenalidomide, Free Base, >99%       Prices Reduced (June 2010)

[CC-5013] [CDC-501] [ENMD-0997] [Revamid] [Revimid] [related term:  Revlimid] [CC 5013] [CC5013] [CDC 501] [CDC501] [ENMD 0997] [ENMD0997]

M.W. 259.26

C13H13N3O3

[191732-72-6]

M.I. 14:  5436

Storage:  Store at or below -20 ºC.  Solubility:  Soluble in DMSO at 100 mg/mL; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 20-100 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility.  Disposal:  A

Find and View a Certificate of Analysis for this product

View the MSDS for this product

• Lenalidomide is a derivative of thalidomide and has immunomodulatory activities.  It has more potent anti-tumor, anti-inflammatory effects, but less adverse effects than thalidomide.  Hideshima, T., et al.  "A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma."  Ther. Clin. Risk Manag. 4:  129-136 (2008).

• Lenalidomide induces G0/G1 growth arrest and apoptosis and has direct anti-tumor activities.  Hideshima, T., et al.  "Thalidomide and its analogues overcome drug resistance of human multiple myeloma cells to conventional therapy."  Blood 96:  2943-2950 (2000).

• Lenalidomide inhibits growth factor-induced angiogenesis in vivo.  Dredge, K., et al.  "Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro."  Microvasc. Res. 69:  56-63 (2005).

• Lenalidomide modulates and potentiates host immune responses against multiple myeloma.  Hayashi, T., et al.  "Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells:  clinical application."  Br. J. Haematol. 128:  192-203 (2005).

• Lenalidomide plus dexamethasone treatment is used against both relapsed/refractory and newly diagnosed multiple myeloma patients.  Combination treatment of lenalidomide and dexamethasone is highly effective in both preclinical and clinical studies.  Adverse effects of this combination can be significantly reduced by lowering the dexamethasone dosage.  Hideshima, T., et al.  "A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma."  Ther. Clin. Risk Manag. 4:  129-136 (2008).

• Lenalidomide, as the racemic mixture, is the active ingredient in the drug sold under the trade name Revlimid®.  This drug has been approved in at least one country for use in patients with multiple myeloma and myelodysplastic syndromes.  NOTE:  This lenalidomide product sold by LC Laboratories is NOT Revlimid® and is NOT for human use.

• Two other CAS numbers previously assigned to lenalidomide, 346670-73-3 and 443912-14-9, have been deleted by CAS and are no longer in use.

• Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.

• This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.

• Not available in some countries; not available to some institutions; not available for some uses.